Triplebar, a bio-manufacturing company, has secured $20 million in funding to expand its product portfolio in food and biopharmaceuticals. The company’s Hyper-Throughput™ screening platform integrates hardware, software, biology, and biochemistry to accelerate evolution and miniaturize production. Triplebar’s commercial partners use the platform to develop animal cell lines for cellular meat products, produce low-cost and low-footprint animal proteins to replace traditional animal sources, and discover novel therapeutic biologic drug candidates for major human health challenges.
Synthesis Capital led the funding round, with participation from Essential Capital, Stray Dog Capital, iSelect Fund, and major investor The Production Board. The investment comes after several years of growth for Triplebar, which is a foundry business of The Production Board. TPB was the first and major investor in Triplebar and has a vision to re-engineer global production systems across food, agriculture, biomanufacturing, human health, and the broader life sciences.
Triplebar’s new funding will help it scale up production to bring entire portfolios of bioproducts to market and help a wide range of companies from incumbents to startups. In January 2023, Triplebar partnered with global ingredients giant FrieslandCampina to co-develop and scale up the production of ingredients essential to human nutrition. The two companies will produce microbial cells via fermentation methodologies, which can produce proteins with a much smaller land, water, and energy footprint than traditional livestock.
In early 2023, Triplebar also partnered with Umami Bioworks, a cultivated seafood platform company, to co-develop optimized cell lines suitable for large-scale production of cultivated seafood. Together, the two companies will work to improve the fitness and performance of cell lines to enable lower-cost, more efficient production of cultivated foods. Umami Bioworks will leverage Triplebar’s Hyper-Throughput™ screening platform for solution discovery and accelerate cell line development and optimization without the need for genetic modification.
